Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

51.76USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$51.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,006,456
52-wk High
$70.04
52-wk Low
$50.56

Latest Key Developments (Source: Significant Developments)

Mercy Investment Services Says Urges Bristol Myers Shareholders To Vote For Proposal #4
Friday, 23 Mar 2018 

March 23 (Reuters) - Bristol-Myers Squibb Co ::MERCY INVESTMENT SERVICES - AT BRISTOL-MYERS SHAREHOLDERS’ MEETING, SHAREHOLDERS WILL HAVE CHANCE TO VOTE ON PROPOSAL SPONSORED BY MULTIPLE SHAREHOLDERS.MERCY INVESTMENT SERVICES - CORE PROPOSAL REQUEST FOR BOARD TO EXPLAIN WHETHER, HOW BMS’ INCENTIVE COMPENSATION ARRANGEMENTS INCORPORATE PUBLIC CONCERN ABOUT HIGH DRUG PRICES.MERCY INVESTMENT SERVICES SAYS URGES BRISTOL MYERS SHAREHOLDERS TO VOTE FOR PROPOSAL #4 - SEC FILING.  Full Article

Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin
Friday, 23 Mar 2018 

March 22 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​.LIGAND - PURSUANT TO AMENDMENT, RETROPHIN PAID CO $4.6 MILLION, WHICH COVERED AMOUNT DUE UPON INITIATION OF FIRST PHASE 3 TRIAL FOR SPARSENTAN​.LIGAND -CO TO PAY $3 MILLION OF AMOUNT PAID BY RETROPHIN TO BRISTOL-MYERS SQUIBB PURSUANT TO AGREEMENT DATED MAY 27 2006 BETWEEN CO, BRISTOL-MYERS SQUIBB​.  Full Article

Mylan Launches Generic Mutamycin Injection For Cancer
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Mylan Nv ::MYLAN ADDS TO GROWING ONCOLOGY PORTFOLIO WITH LAUNCH OF GENERIC MUTAMYCIN® INJECTION.MYLAN NV - ‍U.S. LAUNCH OF ONCOLOGY DRUG MITOMYCIN FOR INJECTION USP, 5 MG/VIAL, 20 MG/VIAL AND 40 MG/VIAL SINGLE DOSE VIALS​.  Full Article

Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates
Monday, 12 Mar 2018 

March 12 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN RESTRUCTURES LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB TO REDUCE ROYALTIES PAYABLE ON ITS MIGRAINE PRODUCT CANDIDATES; TRANSACTION FINANCED THROUGH PRIVATE PLACEMENT WITH LEADING INSTITUTIONAL INVESTORS.BIOHAVEN PHARMACEUTICAL-CO TO PAY BMS UPFRONT PAYMENT OF $50 MILLION IN RETURN FOR LOW SINGLE DIGIT REDUCTION IN ROYALTIES ON NET SALES OF RIMEGEPANT​.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - ‍UPFRONT PAYMENT FOR RESTRUCTURING FINANCED THROUGH PRIVATE PLACEMENT OF CO COMMON SHARES TO INVESTORS​.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - ‍BIOHAVEN'S OBLIGATIONS TO MAKE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS TO BMS REMAIN UNCHANGED​.BIOHAVEN PHARMACEUTICAL HOLDING - ‍RESTRUCTURING OF AGREEMENT WITH BRISTOL-MYERS FOR SMALL MOLECULE CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST PLATFORM​.BIOHAVEN PHARMACEUTICAL HOLDING CO - CO WILL PAY BMS $50 MILLION IN RETURN FOR A MID-SINGLE DIGIT REDUCTION IN ROYALTIES PAYABLE ON NET SALES OF BHV-3500​.BIOHAVEN PHARMACEUTICAL-‍RESTRUCTURING WAS FINANCED THROUGH A $55 MILLION PRIVATE PLACEMENT OF 2 MILLION BIOHAVEN COMMON SHARES AT A PRICE OF $27.50 PER SHARE​.  Full Article

Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer
Thursday, 8 Mar 2018 

March 8 (Reuters) - Bavarian Nordic A/S ::BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER.BAVARIAN NORDIC A/S - CO, ‍BRISTOL-MYERS SQUIBB AGREE TO SUPPLY CLINICAL MATERIAL FOR TRIAL​.BAVARIAN NORDIC A/S - ‍PHASE 2 RANDOMIZED TRIAL WILL ENROLL UP TO 74 PATIENTS​.  Full Article

Bristol-Myers Squibb's Opdivo Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB'S OPDIVO® (NIVOLUMAB) NOW THE FIRST AND ONLY FDA-APPROVED PD-1 INHIBITOR TO OFFER EVERY FOUR-WEEK DOSING.BRISTOL-MYERS SQUIBB - ‍ OPDIVO ALSO WAS APPROVED FOR A SHORTER 30-MINUTE INFUSION ACROSS ALL APPROVED INDICATIONS​.BRISTOL-MYERS SQUIBB - FDA APPROVES OPDIVO LABEL UPDATE OFFERING FLEXIBLE FLAT-DOSING OPTIONS EVERY TWO WEEKS (240 MG) OR EVERY FOUR WEEKS (480 MG)​.BRISTOL-MYERS SQUIBB CO - ‍DOSING SCHEDULE UPDATES FOR AN ADDITIONAL APPROVED INDICATION FOR OPDIVO MAY BE SUBMITTED TO FDA IN FUTURE FOR OPDIVO​.  Full Article

Bristol-Myers Squibb Announces Dividend Increase
Friday, 2 Mar 2018 

March 1 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND INCREASE.BRISTOL-MYERS SQUIBB CO - ‍DECLARED A QUARTERLY DIVIDEND OF FORTY CENTS PER SHARE ON $.10 PAR VALUE COMMON STOCK.BRISTOL-MYERS SQUIBB CO - ‍DECLARED A QUARTERLY DIVIDEND OF FIFTY CENTS PER SHARE ON $2.00 CONVERTIBLE PREFERRED STOCK​.  Full Article

Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB.HEAT BIOLOGICS SAYS COMBINATION OF HS-110 AND NIVOLUMAB WAS WELL TOLERATED - SEC FILING.HEAT BIOLOGICS - IN PHASE 2 CLINICAL TRIAL OF HS-110 AND NIVOLUMAB, OVERALL RESPONSES APPEARED DURABLE AND LONG LASTING‍​.  Full Article

Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Sirenas-:SIRENAS ENTERS INTO MULTI-TARGET COLLABORATION WITH BRISTOL-MYERS SQUIBB.‍SIRENAS SAYS CO WILL RECEIVE AN UNDISCLOSED UP-FRONT PAYMENT, FUNDING FOR RESEARCH ACTIVITIES AND POTENTIAL SUCCESS FEES FROM BRISTOL-MYERS SQUIBB​.‍BRISTOL-MYERS HAS OPTION TO LICENSE COMPOUNDS IDENTIFIED FROM COLLABORATIVE EFFORTS UNDER A SEPARATE AGREEMENT.ENTERED INTO AGREEMENT WITH BRISTOL-MYERS SQUIBB TO DEPLOY CO'S DRUG DISCOVERY PLATFORM TO IDENTIFY POTENTIAL DRUG CANDIDATES.  Full Article

Bristol-Myers Squibb Says Key Lung Cancer Trial Meets Main Goal
Monday, 5 Feb 2018 

Feb 5 (Reuters) - Bristol-Myers Squibb Co ::PIVOTAL PHASE 3 CHECKMATE -227 STUDY DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL (PFS) WITH THE OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH HIGH TUMOR MUTATION BURDEN (TMB).BRISTOL-MYERS - PHASE 3 CHECKMATE -227 STUDY MET CO-PRIMARY ENDPOINT OF PFS WITH OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY.BRISTOL-MYERS - TRIAL WILL CONTINUE AS PLANNED TO ASSESS OPDIVO-YERVOY COMBO FOR OTHER CO-PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH PD-L1 TUMORS.  Full Article

UPDATE 1 Bristol-Myers profit tops Street view, raises 2018 forecast

NEW YORK, April 26 Bristol-Myers Squibb Co on Thursday reported a first-quarter profit that exceeded Wall Street estimates on strong demand for its two most important medicines, and the U.S. drugmaker significantly raised its full-year earnings forecast.